AU2012312126B2 - Vaccine therapy - Google Patents
Vaccine therapy Download PDFInfo
- Publication number
- AU2012312126B2 AU2012312126B2 AU2012312126A AU2012312126A AU2012312126B2 AU 2012312126 B2 AU2012312126 B2 AU 2012312126B2 AU 2012312126 A AU2012312126 A AU 2012312126A AU 2012312126 A AU2012312126 A AU 2012312126A AU 2012312126 B2 AU2012312126 B2 AU 2012312126B2
- Authority
- AU
- Australia
- Prior art keywords
- antigenic peptide
- memory
- peptide
- syndrome
- aci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2011/052992 | 2011-09-23 | ||
| USPCT/US2011/052992 | 2011-09-23 | ||
| PCT/US2012/056728 WO2013044147A1 (en) | 2011-09-23 | 2012-09-21 | Vaccine therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2012312126A1 AU2012312126A1 (en) | 2014-03-27 |
| AU2012312126B2 true AU2012312126B2 (en) | 2016-11-10 |
Family
ID=47018510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2012312126A Active AU2012312126B2 (en) | 2011-09-23 | 2012-09-21 | Vaccine therapy |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20240270829A1 (enExample) |
| EP (1) | EP2758071B1 (enExample) |
| JP (1) | JP6110861B2 (enExample) |
| KR (3) | KR102129220B1 (enExample) |
| CN (2) | CN104039346A (enExample) |
| AU (1) | AU2012312126B2 (enExample) |
| BR (1) | BR112014006871A2 (enExample) |
| CA (1) | CA2811188C (enExample) |
| DK (1) | DK2758071T3 (enExample) |
| EA (1) | EA032494B1 (enExample) |
| ES (1) | ES2712951T3 (enExample) |
| HU (1) | HUE041277T2 (enExample) |
| IL (1) | IL231564A0 (enExample) |
| MX (1) | MX350928B (enExample) |
| MY (1) | MY169574A (enExample) |
| PH (1) | PH12014500657A1 (enExample) |
| PL (1) | PL2758071T3 (enExample) |
| PT (1) | PT2758071T (enExample) |
| SG (1) | SG11201400795UA (enExample) |
| SI (1) | SI2758071T1 (enExample) |
| TR (1) | TR201901846T4 (enExample) |
| WO (1) | WO2013044147A1 (enExample) |
| ZA (1) | ZA201402071B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP2017512751A (ja) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | タウペプチド、抗タウ抗体、およびそれらの使用方法 |
| CA3118692A1 (en) | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| SG11202112329RA (en) * | 2019-05-21 | 2021-12-30 | Ac Immune Sa | Anti-abeta vaccine therapy |
| KR20250137159A (ko) | 2023-01-26 | 2025-09-17 | 에이씨 이뮨 에스에이 | 항-a베타 백신 요법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007068411A2 (en) * | 2005-12-12 | 2007-06-21 | Ac Immune S.A. | Therapeutic vaccine |
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9811401A (pt) | 1997-08-28 | 2000-08-29 | Ajay North America E Som Iodo | Processos para proteger uma substância agrìcola contra pestes que são nocivas para a substância agrìcola e para a proteção de uma substãncia agrìcola, e, composição protetora para substâncias agrìcolas |
| AU2003292936A1 (en) | 2002-12-24 | 2004-07-22 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| NZ567324A (en) * | 2003-02-01 | 2009-08-28 | Wyeth Corp | Active immunization to generate antibodies to soluble A-beta |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| JP4696079B2 (ja) * | 2003-12-17 | 2011-06-08 | ヤンセン アルツハイマー イミュノセラピー | Ａβ免疫原性ペプチド担体結合物およびそれの製造方法 |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| NZ581835A (en) * | 2007-06-12 | 2012-09-28 | Ac Immune Sa | Monoclonal anti beta amyloid antibody |
-
2011
- 2011-09-23 CA CA2811188A patent/CA2811188C/en active Active
- 2011-09-23 KR KR1020197008710A patent/KR102129220B1/ko active Active
- 2011-09-23 KR KR1020137002631A patent/KR20160005380A/ko not_active Ceased
- 2011-09-23 KR KR1020167021791A patent/KR20160099732A/ko not_active Ceased
-
2012
- 2012-09-21 BR BR112014006871A patent/BR112014006871A2/pt not_active Application Discontinuation
- 2012-09-21 EP EP12772616.4A patent/EP2758071B1/en active Active
- 2012-09-21 HU HUE12772616A patent/HUE041277T2/hu unknown
- 2012-09-21 ES ES12772616T patent/ES2712951T3/es active Active
- 2012-09-21 CN CN201280057432.5A patent/CN104039346A/zh active Pending
- 2012-09-21 PT PT12772616T patent/PT2758071T/pt unknown
- 2012-09-21 EA EA201400376A patent/EA032494B1/ru not_active IP Right Cessation
- 2012-09-21 WO PCT/US2012/056728 patent/WO2013044147A1/en not_active Ceased
- 2012-09-21 CN CN201910160828.6A patent/CN109847058A/zh active Pending
- 2012-09-21 JP JP2014532040A patent/JP6110861B2/ja active Active
- 2012-09-21 PH PH1/2014/500657A patent/PH12014500657A1/en unknown
- 2012-09-21 MX MX2014003325A patent/MX350928B/es active IP Right Grant
- 2012-09-21 MY MYPI2014000851A patent/MY169574A/en unknown
- 2012-09-21 TR TR2019/01846T patent/TR201901846T4/tr unknown
- 2012-09-21 SI SI201231487T patent/SI2758071T1/sl unknown
- 2012-09-21 DK DK12772616.4T patent/DK2758071T3/en active
- 2012-09-21 PL PL12772616T patent/PL2758071T3/pl unknown
- 2012-09-21 AU AU2012312126A patent/AU2012312126B2/en active Active
- 2012-09-21 SG SG11201400795UA patent/SG11201400795UA/en unknown
-
2014
- 2014-03-18 IL IL231564A patent/IL231564A0/en active IP Right Grant
- 2014-03-20 ZA ZA2014/02071A patent/ZA201402071B/en unknown
-
2023
- 2023-12-22 US US18/395,150 patent/US20240270829A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007068411A2 (en) * | 2005-12-12 | 2007-06-21 | Ac Immune S.A. | Therapeutic vaccine |
| WO2010106127A2 (en) * | 2009-03-18 | 2010-09-23 | Ac Immune S.A. | Method for therapeutic use |
Non-Patent Citations (1)
| Title |
|---|
| STOLTZNER et al., American Journal of Pathology, 2000, Vol. 156, No. 2, Pages 489-499. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014531455A (ja) | 2014-11-27 |
| KR20160005380A (ko) | 2016-01-15 |
| MX2014003325A (es) | 2014-05-21 |
| NZ622653A (en) | 2015-12-24 |
| HUE041277T2 (hu) | 2019-05-28 |
| KR20190035948A (ko) | 2019-04-03 |
| PT2758071T (pt) | 2019-01-11 |
| PL2758071T3 (pl) | 2019-08-30 |
| TR201901846T4 (tr) | 2019-03-21 |
| ES2712951T3 (es) | 2019-05-16 |
| AU2012312126A1 (en) | 2014-03-27 |
| EP2758071A1 (en) | 2014-07-30 |
| MX350928B (es) | 2017-09-26 |
| DK2758071T3 (en) | 2019-02-18 |
| WO2013044147A1 (en) | 2013-03-28 |
| IL231564A0 (en) | 2014-04-30 |
| CA2811188C (en) | 2020-04-28 |
| KR102129220B1 (ko) | 2020-07-02 |
| CN104039346A (zh) | 2014-09-10 |
| EA201400376A1 (ru) | 2014-09-30 |
| ZA201402071B (en) | 2017-08-30 |
| US20240270829A1 (en) | 2024-08-15 |
| EA032494B1 (ru) | 2019-06-28 |
| CA2811188A1 (en) | 2013-03-23 |
| JP6110861B2 (ja) | 2017-04-05 |
| SI2758071T1 (sl) | 2019-01-31 |
| EP2758071B1 (en) | 2018-11-28 |
| KR20160099732A (ko) | 2016-08-22 |
| MY169574A (en) | 2019-04-22 |
| BR112014006871A2 (pt) | 2017-04-04 |
| SG11201400795UA (en) | 2014-10-30 |
| PH12014500657A1 (en) | 2014-05-05 |
| CN109847058A (zh) | 2019-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240270829A1 (en) | Vaccine Therapy | |
| JP5249043B2 (ja) | 治療ワクチン | |
| RU2551782C2 (ru) | Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами | |
| US8926983B2 (en) | Method for improving memory in AD patients | |
| JP2019163268A (ja) | 病理学的タウタンパク質の免疫学的標的化方法 | |
| US20140314837A1 (en) | Vaccine Therapy | |
| NZ622653B2 (en) | Vaccine therapy for the treatment of memory and/or cognitive impairments in subjects with down’s syndrome | |
| HK1197732A (en) | Vaccine therapy | |
| HK1197732B (en) | Vaccine therapy | |
| HK40100443A (en) | Immunological targeting of pathological tau proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |